A Phase 3 interventional study of ZD9393 (Zoladex) 10.8 mg and ZD9393 (Zoladex) 3.6 mg in Breast Cancer, sponsored by AstraZeneca. Completed at 55 sites in 6 countries. Open to female participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-12-12.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.
Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2010, is one of 15 in phase 3, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
TerSera Therapeutics LLC · Sites in United States
Ages 18–55 · Women only
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 20 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 22 · Phase 3 16 · Phase 4 1
First in 1990; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 147 across the 41 interventional studies. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 50th largest by enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2010, is one of 46 in phase 3, and was the 84th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
2 of the studies testing goserelin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT07310420TerSera Therapeutics LLCA Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing goserelin in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced breast cancer who were randomised in a 1:1 ratio to either of the two treatment groups; the ZD9393 3.6 mg depot group or ZD9393 10.8 mg depot group, both given in combination with tamoxifen tablets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days). One oral tamoxifen 20 mg tablet also will be taken daily
Drug: ZD9393 (Zoladex) 10.8 mg
Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
Drug: ZD9393 (Zoladex) 3.6 mg
10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
Also known as: Zoladex
3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
Also known as: Zoladex
Number of Patients With Progression-free Survival (PFS) at 24 Weeks
A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS.
Time frame: 24 weeks after the first dosing
Number of Responders at 24 Weeks
Responders are defined as those patients with a best objective tumour response of CR or PR during the first 24 weeks of therapy. Tumour response is assessed according to the RECIST version 1.1. ORR is defined as the proportion of patients who are responders.
Time frame: 24 weeks after the first dosing
Oestradiol (E2) Serum Concentrations at 24 Weeks
E2 serum concentrations (pg/mL) at 24 weeks
Time frame: 24 weeks after the first dosing
Totally 286 patients were screened to the study from 58 centres in the following 6 countries: India, Japan, Korea, Philippines, Thailand, Taiwan. The first patient entered the study on 26 February 2010 and the last visit of last patient was on 19 September 2012.
| Milestone | Zoladex 10.8 mg | Zoladex 3.6 mg |
|---|---|---|
| Started | 109 | 113 |
| Received randomised treatment | 108 | 113 |
| Completed | 81 | 74 |
| Not completed | 28 | 39 |
| Withdrew: Reasons other than below | 19 | 31 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Withdrawal by subject | 5 | 5 |
A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS.
| Participants | Zoladex 10.8 mg | Zoladex 3.6 mg |
|---|---|---|
| Number of Patients With Progression-free Survival (PFS) at 24 Weeks | 67 | 68 |
Responders are defined as those patients with a best objective tumour response of CR or PR during the first 24 weeks of therapy. Tumour response is assessed according to the RECIST version 1.1. ORR is defined as the proportion of patients who are responders.
| Participants | Zoladex 10.8 mg | Zoladex 3.6 mg |
|---|---|---|
| Number of Responders at 24 Weeks | 21 | 25 |
E2 serum concentrations (pg/mL) at 24 weeks
| pg/mL | Zoladex 10.8 mg | Zoladex 3.6 mg |
|---|---|---|
| Oestradiol (E2) Serum Concentrations at 24 Weeks | 20.302 ± 12.251 | 24.798 ± 28.149 |
Collected over Non serious AEs and SAEs were be collected from the time of patient informed until 4 weeks after the final administration of ZOLADEX 3.6 mg or 12 weeks after the final administration of ZOLADEX 10.8 mg. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoladex 10.8 mg | 4/108 (3.7%) | 4/108 (3.7%) | 47/108 (43.5%) |
| Zoladex 3.6 mg | 3/113 (2.7%) | 8/113 (7.1%) | 52/113 (46%) |
| Event | Zoladex 10.8 mg | Zoladex 3.6 mg |
|---|---|---|
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/108 | 3/113 |
| ANAEMIABlood and lymphatic system disorders | 1/108 | 1/113 |
| TETANUSInfections and infestations | 1/108 | 0/113 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 1/108 | 0/113 |
| CHEST PAINGeneral disorders | 1/108 | 0/113 |
| ENTEROCOLITISGastrointestinal disorders | 0/108 | 1/113 |
| PERIODONTAL DISEASEGastrointestinal disorders | 0/108 | 1/113 |
| VOMITINGGastrointestinal disorders | 0/108 | 1/113 |
| PNEUMONIAInfections and infestations | 0/108 | 1/113 |
| MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders | 0/108 | 1/113 |
| Event | Zoladex 10.8 mg | Zoladex 3.6 mg |
|---|---|---|
| HOT FLUSHVascular disorders | 15/108 | 22/113 |
| NASOPHARYNGITISInfections and infestations | 13/108 | 9/113 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/108 | 9/113 |
| NAUSEAGastrointestinal disorders | 2/108 | 9/113 |
| HEADACHENervous system disorders | 7/108 | 7/113 |
| PYREXIAGeneral disorders | 2/108 | 7/113 |
| INSOMNIAPsychiatric disorders | 3/108 | 6/113 |
| CONSTIPATIONGastrointestinal disorders | 4/108 | 5/113 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 3/108 | 5/113 |
| VOMITINGGastrointestinal disorders | 4/108 | 3/113 |
| Age, Continuous(years) | Zoladex 10.8 mg | Zoladex 3.6 mg | Total |
|---|---|---|---|
| Mean | 40.9 ± 6.9 | 40.9 ± 6.0 | 40.9 ± 6.4 |
| Sex: Female, Male(Participants) | Zoladex 10.8 mg | Zoladex 3.6 mg | Total |
|---|---|---|---|
| Female | 109 | 113 | 222 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Zoladex 10.8 mg | Zoladex 3.6 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 109 | 113 | 222 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Zoladex 10.8 mg | Zoladex 3.6 mg | Total |
|---|---|---|---|
| Asian | 109 | 113 | 222 |
| Other | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Zoladex 10.8 mg | Zoladex 3.6 mg | Total |
|---|---|---|---|
| Asia — India | 29 | 27 | 56 |
| Asia — Japan | 29 | 30 | 59 |
| Asia — Philippines | 21 | 23 | 44 |
| Asia — Thailand | 10 | 9 | 19 |
| Asia — Taiwan | 7 | 9 | 16 |
| Asia — Republic of Korea | 13 | 15 | 28 |
Ran from Feb 2010 to primary completion in Sep 2012, 30 months.
Results were first posted in Jan 2014, 1 year 3 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 30 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goserelin